Gain Therapeutics, Inc. Leases Disclosure
8. Operating Leases
The Company leases offices in Bethesda (United States), Lugano (Switzerland), and Barcelona (Spain). The current lease portfolio consists of leases with remaining terms ranging from less than year to five years. Certain of the Company’s leases include options to extend or terminate the lease. Renewal options are included in the calculation of ROU assets and lease liabilities when the Company is reasonably certain that renewal options will be exercised. Periods subject to termination options are included in the lease term only when the Company is reasonably certain not to exercise the termination option. The Company’s lease agreements do not contain residual value guarantees or material restrictive covenants.
The breakdown of the significant components of ROU assets, lease liabilities and operating lease expense is reported in the table below, together with the discount rate used in order to calculate the net present value of the lease liabilities as of those periods.
| December 31, | | December 31, | |||
2025 | 2024 | |||||
Operating lease |
| |
| | ||
Operating lease right-of-use assets | $ | 334,090 | $ | 219,715 | ||
Operating lease liabilities - current | $ | 119,876 | $ | 160,913 | ||
Operating lease liabilities - noncurrent | $ | 211,238 | $ | 53,598 | ||
Weighted average remaining lease term - years |
| 3.77 |
| 1.38 | ||
Weighted average discount rate |
| 3.83 |
| 1.53 | ||
The operating lease expenses are reported as follows:
December 31, | December 31, | ||||
2025 | | 2024 | |||
Research and development | $ | 139,355 | $ | 140,577 | |
General and administrative | 38,563 | 88,499 | |||
Total operating lease costs | $ | 177,918 | $ | 229,076 | |
In the years ended December 31, 2025 and 2024, the Company incurred short-term lease expense of $71 thousand and $18 thousand, respectively. These expense were recognized on a straight-line basis and reported within general and administrative costs.
The variable lease costs incurred in the years ended December 31, 2025 and 2024 was $31 thousand and $25 thousand, respectively.
The Company made fixed cash payments related to operating leases of $0.2 million in both the years ended December 31, 2025 and 2024.
The future minimum lease payments for the Company’s operating leases as of December 31, 2025, are as follows:
Fiscal Year | | Operating Leases | |
2026 | $ | 127,435 | |
2027 | 81,624 | ||
2028 | 49,281 | ||
2029 | 50,562 | ||
2030 | 51,877 | ||
Total future minimum lease payments | 360,779 | ||
Less amount representing interest or imputed interest | 29,665 | ||
Present value of lease liabilities | $ | 331,114 | |
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 26, 2026 | Showing above |
| 2024 | Mar 27, 2025 | |
| 2023 | Mar 26, 2024 | |
| 2022 | Mar 23, 2023 | |
About Leases Disclosures
Lease disclosures under ASC 842 provide a comprehensive view of a company's leased asset portfolio, including the split between operating and finance leases, discount rates used to present-value future payments, and the maturity schedule of lease obligations. This section reveals a significant source of off-balance-sheet commitments that were largely hidden before the current standard.
Key signals: the weighted-average discount rate affects the size of recorded lease liabilities — a higher rate reduces the reported obligation, so compare the chosen rate against the company's incremental borrowing rate. The operating versus finance lease mix affects both EBITDA and operating income presentation. Watch the maturity table for concentration risk: large payment cliffs in specific years may create cash flow pressure. Variable lease payments excluded from the liability measurement represent real obligations that do not appear on the balance sheet. Compare total lease costs against prior-year operating lease expense to assess the true economic burden.